{
    "clinical_study": {
        "@rank": "26689", 
        "arm_group": {
            "arm_group_label": "Desmopressin", 
            "arm_group_type": "Experimental", 
            "description": "Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis"
        }, 
        "brief_summary": {
            "textblock": "Prolonged Collagen/Epinephrine - closure time (CEPI-CT) indicates platelet dysfunction in\n      CKD patients taking antiplatelet agent. The synthetic vasopressin derivative, Desmopressin\n      (DDAVP) shortens the prolonged bleeding time and improves platelet dysfunction measured by\n      in vitro closure time: CEPI-CT in uremic patients. Desmopressin also antagonizes the in\n      vitro platelet dysfunction induced by GPIIb/IIIa inhibitors, clopidogrel and aspirin. The\n      investigators designed a prospective study to evaluate the effect of desmopressin on\n      platelet function, as measured by in vitro collagen/epinephrine - closure time, in uremic\n      patients who were taking antiplatelet drugs."
        }, 
        "brief_title": "Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Bleeding", 
            "Tachycardia", 
            "Dyspnea"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dyspnea", 
                "Hemorrhage", 
                "Tachycardia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult uremic patients with one or more antiplatelet medication,\n\n          -  prolonged collagen/epinephrine (CEPI) closure time,\n\n          -  need for emergent hemodialysis and\n\n          -  subsequent catheter insertion\n\n        Exclusion Criteria:\n\n          -  acute coronary syndrome,\n\n          -  hemophilia, and nephrogenic diabetes insipidus,\n\n          -  allergy against desmopressin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841515", 
            "org_study_id": "NCT00134031"
        }, 
        "intervention": {
            "arm_group_label": "Desmopressin", 
            "intervention_name": "Desmopressin administration", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Deamino Arginine Vasopressin", 
                "Platelet Aggregation Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Songpa-gu", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "In vitro closure time (CT), measured using a platelet function analyzer (PFA)-100, is a relatively new tool for investigation of primary hemostasis. This system has been shown to be efficacious in evaluating abnormalities of primary hemostasis.", 
            "measure": "collagen-epinephrine closure time", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841515"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Ulsan", 
            "investigator_full_name": "Soon Bae Kim, M.D., PhD.", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "we observe incidence of bleeding complication after procedure", 
            "measure": "Bleeding after procedure", 
            "safety_issue": "No", 
            "time_frame": "1-4 hr after procedure"
        }, 
        "source": "University of Ulsan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Ulsan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}